Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Publication information:
Zoeller J, Vagodny A, Daniels V, Taneja K, Tan B, DeRose Y, Fujita M, Welm A, Letai, Leverson J, Blot V, Bronson R, Dillon D, Brugge J. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Breast Cancer Res. 2020;22(Nov 30):132.